Avacta Group plc partners with GlytheraAntibody Drug Conjugate (ADC) specialist Glythera has licensed Actava Group’s Affimer technology in order to develop drug conjugates using the combined technologies. Affimers are small, stable … more ➔
European biotech stocks: 2017 with strong...In 2017, the stock market was a strong financial resource for the European biotech sector – with a significant volume increase in IPOs and follow-on financings compared to 2016. This says the most recent … more ➔
Western diet triggers inflammatory disease...Immunologists headed by Eicke Latz (Univ. of Bonn, Germany) have found out that calorie-rich, fatty Western diet reprogrammes the innate immune system to become hyperreactive to inflammatory triggers. … more ➔
Scientists crack down immune cells that pr...So far, there is no cure to stop fibrosis, the pathogenic proliferation of connective tissue of the skin and in organs, in autoimmune diseases such as systemic sclerosis (scleroderma). An US-Italian … more ➔
Truffle Capital closes new BioMedTech vent...French venture capitalist Truffle Capital announced the first closing of its BioMedTech venture fund aimed at investments into North American and European medical devices and biotechnology start-ups … more ➔
Ablynx rejects Novo’s €2.3bn bidNanobody developer Ablynx NV has stated that the take-over cash price of €28 per share + optional €2.50 per share as Contingent Value Right (CVR) offered by Novo Nordisk A/S at the end of December … more ➔
Roche further expands in digital medicineGlobal theranostics major Roche expands its digitalised medicine portfolio. The next agreed project is a digital diagnostics platform to improve oncology and critical care treatment. more ➔
New method identifies harmful medicines me...A new method to test the likelihood of a drug turning into a potentially harmful version of itself when it enters the body has been developed by researchers at Cardiff University. more ➔
Takeda bids €520m for TiGenixJapanese Pharma major Takeda had announced its intention to take over Belgian adipose stem cell therapy specialist Tigenix, which has already exclusively licenced its lead product darvadstrocel (Cx601) … more ➔
Boehringer Ingelheim expands Venture Funds... German human and veterinay medicines major Boehringer Ingelheim has more than doubled the amount in funding of its Venture Fund (BIVF) to €250m. Additionally, the investment focus has been extended … more ➔
